Table 1 HPV type-specific risks and population attributable proportions for the development of histopathologically confirmed high-grade CIN during a mean follow-up time of 4 years in a cohort of 5696 women

From: HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study

HPV type

Absolute risk of CIN2+ ((95% C), CIN2+ cases/women infected)

Absolute risk of CIN3+ ((95% CI), CIN3+ cases/women infected)

Relative rate a for CIN 2+ (95% CI)

Relative rate b , c for CIN 2+ (95% CI)

Population attributable proportion (95% CI)

HPV negative

0.40% (0.25–0.61) 21/5235

0.19% (0.092–0.35) 10/5235

—

—

—

HPV 16

36.6% (28.7–45.1) 52/142

28.2% (20.9–36.3) 40/142

27.6 (19.7–38.6)

17.4 (12.0–25.1)

33.1% (24.7–40.6)

HPV 18

25.6% (13.0–42.1) 10/39

15.4% (5.9–30.5) 6/39

11.3 (6.0–21.5)

6.3 (3.1–12.5)*

5.7% (1.5–9–7)

HPV 31

36.7% (26.1–48.3) 29/79

22.8% (14.1–33.6) 18/79

20.1 (13.4–30.1)

14.9 (9.7–22.9)

18.3% (11.5–24.5)

HPV 33

48.0% (27.8–68.7) 12/25

28.0% (12.1–49.4) 7/25

27.8 (15.4–50.2)

18.5 (9.1–37.4)

7.7% (3.1–12–0)

HPV 35

9.1% (1.1–29.2) 2/22

4.5% (0.1–22.8) 1/22

4.2 (1.0–16.9)

3.1 (0.8–12.9)**

0.9% (0–2.8)

HPV 39

17.6% (3.8–43.4) 3/17

11.8% (1.5–36.4) 2/17

6.6 (2.1–20.7)

6.0 (1.9–19.4)*

1.7% (0–3.9)

HPV 45

19.2% (9.6–32.5) 10/52

7.7% (2.1–18.5) 4/52

8.3 (4.4–15.8)

0.9 (0.4–2.1)***

—

HPV 51

17.2% (5.8–35.8) 5/29

17.2% (5.8–35.7) 5/29

7.4 (3.0–18.0)

5.3 (1.9–14.7)**

2.7% (0–5.6)

HPV 52

26.1% (10.2–48.4) 6/23

13.0% (2.8–33.6) 3/23

10.9 (4.8–24.6)

4.2 (1.8–9.7)**

3.1% (0–6.3)

HPV 56

10.3% (2.9–24.2) 4/39

2.6% (0.06–13.5) 1/39

4.3 (1.6–11.7)

3.7 (1.3–10.2)**

2.0% (0–4.6)

HPV 58

30.4 (13.2–52.9) 7/23

21.7% (7.5–43.7) 5/23

13.4 (6.3–28.7)

5.9 (2.5–14.1)*

3.9% (0.4–7.3)

HPV 59

0% 0/14

0%

0

0***

—

HPV 66

7.4% (0.9–24.3) 2/27

3.7% (0.0 –19.0) 1/27

3.1 (0.8–12.4)

0.3 (0.07–1.3)***

—

HPV 68

No detected infection

—

—

—

—

HPV 16 and/or HPV 18

34.3% (27.3–41.7) (61/178)

25.3% (19.1–32.3) 45/178

27.4 (19.7–38.0)

18.9 (13.2–27.1)

39.0% (30.2–46.7)

HPV16 and/or 18 and/or 31 and/or 33

56.1% (48.3–63.6) 97/270

24.4% (19.4–30.0) 66/270

47.2 (33.6–66.2)

42.4 (29.9–60.3)

64.0% (55.0–71.2)

All HPV positives

27.5% (23.5–31.9) 127/461

18.4% (15.0–22.3) 85/461

80.8 (50.9–128.3)

80.8 (50.9–128.3)

84.7% (73.3–89.7)

  1. aAdjusted for censoring before or after 6 months of follow-up.
  2. bAdjusted for censoring before or after 6 months of follow-up and for other HPV types.
  3. cType-specific relative rates that were significantly different from HPV 16 relative rate: P-value *0.01<0.05, **0.001<0.01 and ***<0.001.
Back to article page